Mental health evaluation begins on the first day of detox.

The psychiatric assessment identifies co-occurring mental health conditions and guides the detox protocol from admission. At Jintara, this assessment takes place on the first day of admission through one of two addiction-specialist psychiatric services in Chiang Mai: Bangkok Hospital Chiang Mai or RAM Hospital. Both are confirmed transfer partners. The psychiatrist who conducts the assessment is a specialist in addiction medicine, not a generalist.

Many people entering detox carry unaddressed mental health conditions including depression, anxiety, bipolar disorder, ADHD, or responses to trauma that substance use has been managing for years. The assessment surfaces these conditions early so the treatment team can respond to the whole picture, beyond the withdrawal.

Identifying and responding to dual diagnosis and co-occurring conditions from the first day reduces the risk of misreading psychological distress as purely physical withdrawal, which can lead to under-treatment of the real driver.

The NIAAA Core Resource on Alcohol documents the high prevalence of psychiatric comorbidities in people presenting for alcohol use disorder treatment, reinforcing the clinical case for assessment at admission.

The initial assessment is a thorough clinical interview covering six areas. Psychiatric history captures previous diagnoses, prior treatment and hospitalisation, medications tried, what helped or caused problems, and family mental health background. Substance use history covers the timeline, daily amounts, polysubstance patterns, previous detox attempts, and what previous withdrawals felt like.

The current mental status examination looks at orientation, memory, concentration, thought process, mood, and affect. The suicidal ideation question is asked directly, as are questions about self-harm history and psychotic symptoms such as hallucinations or paranoia.

Trauma history is noted, but not processed during detox. Deep trauma work is clinically inappropriate during acute withdrawal because the person's coping capacity is limited and the brain is under physiological stress. Processing is deferred to the therapy phase once the person is stable.

A functional assessment also covers work, relationships, housing, and legal situation, which informs discharge planning and shapes what the admissions process looks like in practice. The clinical evidence base for this co-occurring disorder assessment approach is documented in NIDA's research on comorbidity.

Jintara uses the PHQ-9 at intake for depression and suicidal ideation screening, with the additional 8Q test conducted when the PHQ-9 flags any concern. Denise O'Leary, Clinical Director, notes that more than half of incoming clients have had some thoughts about suicide at some point during active addiction. This is a recognised presentation for this population and does not prevent admission.

The assessment distinguishes passive ideation, a generalised sense that life is not worth living, from active planning with intent and method. Clients with passive ideation are monitored closely through the nursing and therapy team. A client whose suicidal ideation is active and cannot be safely managed within the facility is referred directly to the psychiatric unit at Bangkok Hospital Chiang Mai or RAM Hospital for assessment and stabilisation.

Darren Lockie notes that by the time someone makes the decision to enter treatment, the direction of that choice is toward life. In most cases, active ideation settles once safety and structure are established.

Screening and safety management protocols of this kind are aligned with SAMHSA's clinical guidance for addiction assessment settings. This screening sits within the broader withdrawal monitoring protocol that nursing staff run around the clock.

Co-occurring mental health conditions are often impossible to diagnose accurately while a person is still in active substance use. The brain chemistry is disrupted, sleep is compromised, and the emotional volatility of withdrawal makes it difficult to distinguish genuine pathology from withdrawal physiology.

Depression and anxiety during the first week of detox may reflect the withdrawal itself, may reflect a pre-existing condition, or may reflect both. The psychiatric team makes working assessments rather than fixed diagnoses early in the process and continues to refine the clinical picture as the person stabilises.

One common example is ADHD. Adults presenting with difficulty concentrating, impulsivity, and restlessness during early recovery are frequently identified through the ongoing psychiatric assessment. This changes the therapy approach and, where appropriate, the medication plan, and shapes what the treatment program focuses on once detox stabilises.

Research from the National Institute on Drug Abuse confirms that mental illness and substance use disorders co-occur at significantly elevated rates, and that treatment addressing both conditions produces better outcomes.

The medication plan is psychiatrist-led, informed by the assessment findings and adjusted by nursing observation in real time. The psychiatrist considers substance type, withdrawal severity, psychiatric history, existing medications, and any medical conditions that affect which drugs can be safely used.

A person with a history of depression entering alcohol detox requires balancing seizure prevention medication alongside mood support. A person with generalised anxiety entering benzodiazepine detox requires a slow taper and non-medication anxiety management strategies rather than substitution. Benzo taper, where required, can extend up to two to three months with a minimum three-week post-zero window.

Jintara does not offer naltrexone, acamprosate, disulfiram, or other oral relapse prevention medications after detox. The clinical position, confirmed by Denise O'Leary, is that the program does not recommend using substances to treat substance use. Methadone is used during opioid withdrawal as a taper medication only, not for long-term maintenance.

Specific medications prescribed are determined by the psychiatrist and are the only out-of-pocket cost added to the detox fee. Medication costs at Thai hospital rates are considerably lower than comparable costs elsewhere. The small residential setting at Jintara means nursing staff observe how the medication plan works in practice and escalate to the psychiatrist promptly when adjustment is needed.

The initial assessment is not the only psychiatric contact during a stay at Jintara. The psychiatrist reviews the case as often as the clinical picture requires. If sleep is not stabilising, medication is not achieving what was expected, or new symptoms emerge as withdrawal resolves, the psychiatrist adjusts the plan.

Some clients see the psychiatrist five, six, or seven times during their stay. This frequency is not unusual. It reflects the unpredictable way mental health presents during withdrawal and the week or two of adjustment that follows.

Nursing staff are awake and monitoring around the clock, with vital signs recorded every four to six hours during active detox. These observations feed directly into the next psychiatric review so the psychiatrist works from real behavioural data: sleep patterns, agitation levels, medication response, and mood notes recorded across each shift.

The addiction-specialist psychiatrists at Bangkok Hospital Chiang Mai and RAM Hospital also provide continuity. Generally the same psychiatrist sees the client across multiple reviews rather than a different clinician at each visit. The Jintara clinical team includes nursing staff, therapists, and the consulting psychiatrists who together manage the full detox and treatment period.

Jintara's model does not separate detox from therapy. Psychiatric assessment and initial therapy contact happen on the same day where possible, and by day two at the latest. Denise O'Leary describes the approach as running two parallel tracks from admission: psychiatry provides the medication framework and clinical safety monitoring, while therapy provides psychological safety, stabilisation support, and the early relationship that keeps the person engaged when detox becomes difficult.

The therapy during detox is not deep processing work. It is contact, reassurance, and grounding. No heavy trauma processing takes place while the body is in withdrawal stress. The purpose is to keep the person oriented, to reduce the shame and fear that frequently drives people to leave treatment before it works, and to begin the therapeutic relationship that will carry through the 30-day program.

As withdrawal stabilises, therapy increases in depth and frequency. EMDR therapy is introduced for appropriate clients after medical stabilisation, primarily for those in eight-week or longer programs.

The National Institute of Mental Health confirms that integrated treatment addressing both substance use and mental health produces significantly better outcomes than treating either condition in isolation.